SURVYR

LXRX

Lexicon Pharmaceuticals, Inc.
$1.49
+$0.01 (0.34%)Oct 28 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-21%+8%+36%+64%+93%Oct 2025Oct 2026Apr 202652w high $2.6852w low $1.10
LXRXSPY
Wall St. Highest PT $8.00 (+438.7%) Wall St. Avg PT $4.55 (+206.2%)
$1$3$6$8$10POC $2Hi $8Avg $5
Underwater Drawdown %Max DD -46.2%Current -43.8%
0.0%-46.2%
Relative Strength vs SPY-7.1% vs SPYUnderperforming
+93%0%-93%
1W
−$0.07 (4.81%)
1M
−$0.41 (21.84%)
3M
−$0.83 (35.99%)
6M
−$0.06 (4.19%)
YTD
+$0.34 (29.13%)
1Y
+$0.11 (8.39%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
6 analysts · mean score 1.83
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$1.49
Average target$4.55
+$3.06 (+206.2%) upsideaverage target vs current price
CurrentAverageMedian
Low$2.00
Median$4.55
High$8.00
12-month Wall Street target range
Recent analyst rating changes · 8
Initiated
2026-09-28 · Cantor Fitzgerald started covering LXRX at Overweight
Reiterated
2026-05-11 · Citigroup reiterated Buy on LXRX
Reiterated
2026-03-23 · HC Wainwright & Co. reiterated Buy on LXRX
Reiterated
2026-03-10 · Citigroup reiterated Buy on LXRX
Reiterated
2026-03-05 · HC Wainwright & Co. reiterated Buy on LXRX
Reiterated
2025-09-02 · HC Wainwright & Co. reiterated Buy on LXRX
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$694.1M
P/E (next 12 months, estimated)-8.2
52-week range$1.10 – $2.68
Revenue growth (latest quarter vs a year ago)-97.6%
Dividend yieldNo dividend
Analyst consensusBuy (6)
Average analyst price target$4.55 (+206%)

What they do

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for LXRX yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

LXRX earningsNext report in 8 days
Next report · quarter Sep 2026
Thu Nov 5, 2026Before the open
EPS consensus-$0.05 range -$0.06–-$0.04
Revenue consensus$4.1M 6 analysts
Last 4 quarters · EPS vs estimate
Aug 6, 2026-$0.06est -$0.05−24.8%Below estimates
Mar 5, 2026-$0.04est -$0.07+43.6%Above estimates
Nov 6, 2025-$0.04est -$0.07+39.4%Above estimates
Aug 6, 2025$0.01est -$0.08+112.9%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-21 18:28:46 ET
24-0824-1125-0325-0525-0825-1126-0326-08-0.190.01
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$692.0K-97.6%
2026-03-31$21.1M–
2025-12-31$5.5M–
2025-09-30$14.2M–
2025-06-30$28.9M–

News & catalysts

More news
Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin’s Biological Effects in Cardiovascular Disease
GlobeNewswire · Oct 21
Lexicon Pharmaceuticals (LXRX) Stock Fair Value Rises After SONATA HCM Trial Progress
Simply Wall St. · Oct 02
Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today
Motley Fool · Sep 28
Lexicon Pharmaceuticals Shares Rise After Cantor Fitzgerald Initiates With Overweight Rating
MT Newswires · Sep 28
Lexicon Pharmaceuticals surges as Cantor Fitzgerald sees unencumbered path in HCM
Investing.com · Sep 28
Rating changes
Initiated
2026-09-28 · Cantor Fitzgerald started covering LXRX at Overweight
Reiterated
2026-05-11 · Citigroup reiterated Buy on LXRX
Reiterated
2026-03-23 · HC Wainwright & Co. reiterated Buy on LXRX
Reiterated
2026-03-10 · Citigroup reiterated Buy on LXRX
Reiterated
2026-03-05 · HC Wainwright & Co. reiterated Buy on LXRX
Reiterated
2025-09-02 · HC Wainwright & Co. reiterated Buy on LXRX

Third-party analyst actions, not SURVYR.'s views. All rating changes

Stats refreshed 2026-10-21 18:28:46 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026